Clinical investigationPharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals☆
References (41)
- et al.
Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction
Am J Cardiol
(1995) - et al.
Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992
J Am Coll Cardiol
(1994) - et al.
The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial
Am J Cardiol
(1990) - et al.
Optimal utilization of thrombolytic therapy for acute myocardial infarction: concept and controversies
J Am Coll Cardiol
(1990) - et al.
Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter
Am J Cardiol
(1993) - et al.
Beneficial effect of magnesium sulfate in acute myocardial infarction
Am J Cardiol
(1990) - et al.
Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
Lancet
(1992) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
Lancet
(1986)GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
Lancet
(1990)An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
N Engl J Med
(1993)
Randomized trial of intravenous atenol among 16,027 cases of suspected acute myocardial infarction: ISIS-1
Lancet
(1986)
Randomized trial of intravenous, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
Lancet
(1988)
ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
Lancet
(1992)
Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction
Circulation
(1994)
Cardiovascular disease
JAMA
(1991)
Selection of patients with acute myocardial infarction for thrombolytic therapy
Ann Intern Med
(1990)
Meeting highlights
Circulation
(1994)
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
N Engl J Med
(1995)
Cost effectiveness of thrombolytic therapy in elderly patients with suspected acute myocardial infarction
N Engl J Med
(1992)
Metoprolol in acute myocardial infarction (MIAMI)
Am J Cardiol
(1985)
Cited by (22)
Trends in myocardial infarction treatment in subjects aged 35-64 in Southwestern France, 1986-93
2003, International Journal of CardiologyCardiovascular drug utilization and its determinants in unselected medical patients with ischemic heart disease
2002, European Journal of Internal MedicinePharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals
1999, International Journal of CardiologyAbsence of sex differences in pharmacotherapy for acute myocardial infarction
2004, Canadian Journal of CardiologyImpact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost
2004, American Journal of Managed CarePharmacodynamics of β-blockers in heart failure: Lessons from the Carvedilol Or Metoprolol European Trial
2004, Journal of Cardiovascular Pharmacology and Therapeutics
- ☆
Supported by a research grant from Bristol-Myers Squibb Company.
- 1
Dr. Phillips is the recipient of the 1994–1995 American College of Clinical Pharmacy—Merck & Company Cardiovascular Fellowship.
Copyright © 1996 Published by Mosby, Inc.